News

Lilly's galcanezumab proves successful in three phase 3 migraine studies. Here are the findings.

AstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.

The days of the traditional, channel-focused and largely enshrouded PBM business model have come and gone. Here’s what’s next.

New research shows hypertension, diabetes influence survival of ovarian cancer patients in different ways.

Alcohol consumption is known to be a risk factor for breast cancer based on studies predominantly done in white women. Now, a University of North Carolina Lineberger Comprehensive Cancer Center study has found the same risk exists for black women.

Technology advances in pharmacy include innovations that improve medication safety, efficiency, and patient compliance.

It has been an exciting time at the Myeloma Institute at the University of Arkansas for Medical Sciences, on all fronts, namely, embarking on research that could play an important role in the development of preventative and curative strategies for multiple myeloma in the future.

Value-based drug contracting between manufacturers and payers is picking up steam-appropriate timing as the healthcare industry moves toward value-based payment and purchasing and away from fee-for-service.

Here are three things to consider when developing a population health management team at your organization.

Key socioeconomic data that will help you care for your most vulnerable populations.

FDA approves ribociclib plus letrozole to treat a subset of advanced breast cancer patients.

A new report reveals how personalized medicine can make patients healthier while lowering costs.

Operational issues aside, outcomes-based contracts can offer a two-fold benefit for managed care executives.

What MCOs should know about insurers’ plans for the marketplace exchanges in 2018.

Here are the top three reasons for medication adherence failure and how to overcome them.

The 13th edition EMD Serono Specialty Digest outlines top specialty drug management issues health plans face.

Healthcare executives are starting to realize that preventing cyberattacks is not just a task for their IT departments and third-party security vendors.

A new study led by The University of California researchers and published in JAMA reveals surprising findings.

Industry experts analyze issues of mail delivery and transparency in the prescription drug market.

Based on new data from 2 large clinical trials, FDA is warning that these blockbuster type 2 diabetes medications can cause an increased risk of leg and foot amputations.

FDA expanded the use of ivacaftor (Kalydeco, Vertex Pharmaceuticals) to treat cystic fibrosis.

What are the next steps for the bill, and how likely is it that it will become law? Here’s are four things MCOs should know.

Our policy analyst explains why he believes single payer Medicare-for-all is a pipe dream.

The conference raised important points about value-based contracts and the specialty pharmacy space.

A Willis Towers Watson survey finds that employers see enhancing the employee experience in healthcare as key to boosting health engagement.

Find out how the American College of Physicians says population health data can decrease opioid addiction and abuse.

By 2025, the United States could be facing a shortage ranging from 34,600 to 88,000 physicians in total. Find out how this could affect population health initiatives.

Scott Gottlieb, MD, was sworn in as the new FDA commissioner and ushers in a new era.

Soon after approving the same drug for metastatic Merkel cell carcinoma, FDA approved immuno-oncology avelumab (Bavencio) for locally advanced or metastatic urothelial carcinoma.

Here are four things MCOs should know about a new study focusing on young patients with diabetes.